Приказ основних података о документу

dc.creatorVidaković, Melita
dc.creatorGrdović, Nevena
dc.creatorDinić, Svetlana
dc.creatorMihailović, Mirjana
dc.creatorUskoković, Aleksandra
dc.creatorArambašić Jovanović, Jelena
dc.date.accessioned2017-11-23T11:27:13Z
dc.date.available2017-11-23T11:27:13Z
dc.date.issued2015
dc.identifier.urihttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4528295
dc.identifier.urihttp://ibiss-r.rcub.bg.ac.rs/123456789/2678
dc.identifier.urihttp://journal.frontiersin.org/article/10.3389/fimmu.2015.00403/full#
dc.description.abstractThe pleiotropic chemokine (C-X-C motif) ligand 12 (CXCL12) has emerged as a crucial player in several diseases. The role of CXCL12 in diabetes promotion and progression remains elusive due to its multiple functions and the overwhelming complexity of diabetes. Diabetes is a metabolic disorder resulting from a failure in glucose regulation due to β-cell loss and/or dysfunction. In view of its ability to stimulate the regeneration, proliferation, and survival of β-cells, as well as its capacity to sustain local immune-isolation, CXCL12 has been considered in approaches aimed at attenuating type 1 diabetes. However, a note of caution emerges from examinations of the involvement of CXCL12 in the development of diabetes and its complications, as research data indicate that CXCL12 displays effects that range from protective to detrimental. Therefore, as a beneficial effect of CXCL12 in one process could have deleterious consequences in another, a more complete understanding of CXCL12 effects, in particular its functioning in the cellular microenvironment, is essential before CXCL12 can be considered in therapies for diabetes treatment.
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173020/RS//
dc.relationCOST Action CM1406
dc.rightsopenAccess
dc.sourceFrontiers in immunology
dc.subjectCXCL12
dc.subjectCXCR4
dc.subjectCXCR7
dc.subjectDiabetes mellitus
dc.subjectDiabetic complications
dc.subjectPancreatic β-cells
dc.subject.otherm14
dc.titleThe Importance of the CXCL12/CXCR4 Axis in Therapeutic Approaches to Diabetes Mellitus Attenuation
dc.typearticle
dc.rights.licenseBY
dcterms.abstractМихаиловић, Мирјана; Ускоковић, Aлександра; Динић, Светлана; Видаковић, Мелита; Aрамбашић Јовановић, Јелена; Грдовић, Невена;
dc.rights.holder© 2015 Authors
dc.citation.volume6
dc.description.otherFrontiers in Immunology (2015), 6: 403
dc.identifier.doi10.3389/fimmu.2015.00403
dc.identifier.pmid26300887
dc.identifier.scopus2-s2.0-84938502153
dc.identifier.wos000359470600002
dc.citation.apaVidaković, M., Grdović, N., Dinić, S., Mihailović, M., Uskoković, A., & Arambašić Jovanović, J. (2015). The Importance of the CXCL12/CXCR4 Axis in Therapeutic Approaches to Diabetes Mellitus Attenuation. Frontiers in immunology, 6, 403.
dc.citation.vancouverVidaković M, Grdović N, Dinić S, Mihailović M, Uskoković A, Arambašić Jovanović J. The Importance of the CXCL12/CXCR4 Axis in Therapeutic Approaches to Diabetes Mellitus Attenuation. Front Immunol. 2015;6:403.
dc.citation.spage403
dc.citation.epage403
dc.identifier.fulltexthttp://ibiss-r.rcub.bg.ac.rs/bitstream/handle/123456789/2678/FrontImmunol_2015_6_403.pdf?sequence=1&isAllowed=y


Документи

Thumbnail

Овај рад се појављује у следећим колекцијама

Приказ основних података о документу